William Blair & Company
ALT icon

William Blair & Company’s Altimmune ALT Stock Holding History

William Blair & Company’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93.2K Buy
30,660
+2,437
+9% +$7.28K ﹤0.01% 1692
2026
Q1 		$86.9K Sell
28,223
-28,211
-50% -$120K ﹤0.01% 1614
2025
Q4 		$204K Buy
+56,434
New +$246K ﹤0.01% 1460

Other funds holding ALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

William Blair & Company's ALT Position: Q2 2026 in Review

William Blair & Company increased its Altimmune (ALT) stake by 8.6% in Q2 2026, buying an estimated $7.28K and bringing the position to 30,660 shares worth $93.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1692.

William Blair & Company first reported a position in ALT in Q4 2025 and has held it in 3 quarters since. The position peaked at $204K in Q4 2025. 210 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

  • William Blair & Company held 30,660 shares of Altimmune worth $93.2K as of Q2 2026.
  • William Blair & Company bought 2,437 Altimmune shares in Q2 2026, an estimated $7.28K.
  • Altimmune made up ﹤0.01% of William Blair & Company's portfolio in Q2 2026, its #1692 holding.
  • William Blair & Company first reported a position in Altimmune in Q4 2025 and has held it in 3 quarters since.
  • William Blair & Company's Altimmune position peaked at $204K in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.